Different Platelet Activities Between Intracoronary and Peripheral Blood in Coronary Artery Disease Patients

Summary

Antiplatelet treatment is important for coronary artery disease(CAD) patients .Some patients are resistant to antiplatelet treatment based on platelet function tests(PFT).Currently the results of PFT are mainly based on the analysis of peripheral blood. instead, adverse cardiovascular events in CAD patients may be more directly related to platelet activities in the coronary arteries. There's no evidence of system study to prove the PFT of peripheral blood can represent the platelet functions in coronary arteries.The purpose of this study is to determine the different platelet activities in the blood of peripheral vein (PV), peripheral artery (PA), intracoronary artery (IC) in the CAD patients without or with different interventions.

our study is divided into three parts: Part A: To study the different platelet activities in the blood of PV, PA, IC in the CAD patients with dual antiplatelet therapy.

Part B: To explore the different platelet activities of the above three sites in ST-segment elevation myocardial infarction (STEMI) patients who are administrated platelet membrane glycoprotein Ⅱb/Ⅲa (GPⅡb/Ⅲa) receptor antagonist ( tirofiban ) in PV or IC and dual antiplatelet therapy.

Part C: To explore the different platelet activities of the above three sites in STEMI patients who are administrated antiplatelet thrombolysin or placebo in PV and dual antiplatelet therapy.

Conditions

• Coronary Artery Disease

Interventions

DRUG

tirofiban in PV

a loading dose of 10ug/kg tirofiban is given in 3 min through PV,followed by a maintenance dose of 0.15ug/kg\*min for 48h. (clopidogrel 600 mg+aspirin( ASA) 300 mg)x1 day.

DRUG

tirofiban in IC

a loading dose of 10ug/kg tirofiban is given in 3 min through IC,followed by a maintenance dose of 0.15ug/kg\*min for 48h. (clopidogrel 600 mg+ ASA 300 mg)x1 day.

DRUG

antiplatelet thrombolysin

a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h. (clopidogrel 600 mg+ ASA 300 mg)x1 day.

DRUG

placebo

a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h. (clopidogrel 600 mg+ ASA 300 mg)x1 day.

DRUG

Clopidogrel

loading dose of 300 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days

DRUG

Aspirin

loading dose of 300 mg aspirin followed by a maintenance dose of 100 mg/d for at least 5 days.

DRUG

Clopidogrel

loading dose of 600 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days

Sponsors & Collaborators

• National Natural Science Foundation of China

  collaborator OTHER_GOV

• The First Affiliated Hospital with Nanjing Medical University

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2016-01-01

Primary Completion

2017-11-30

Completion

2017-12-31

Countries

• China

Study Locations